Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2012-04-04

Last Posted Date: 2017-03-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 145

Registration Number: NCT01570751

Locations: 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin glargine
Drug: insulin degludec

First Posted Date: 2012-04-03

Last Posted Date: 2016-02-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01569841

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Minneapolis, Minnesota, United States

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Intracerebral Haemorrhage

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-29

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT01566786

Locations: 🇬🇧
Novo Nordisk Investigational Site, Newcastle, United Kingdom

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-03-29

Last Posted Date: 2016-10-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2223

Registration Number: NCT01565733

Locations: 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Bleeding During/Following Surgery
Acquired Bleeding Disorder

Interventions: Drug: standard therapy
Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-28

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 11

Registration Number: NCT01564563

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0114-0006

First Posted Date: 2012-03-28

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01565408

Locations: 🇷🇺
Novo Nordisk Investigational Site, Yaroslavl, Russian Federation

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Turner Syndrome
Growth Hormone Disorder
Growth Hormone Deficiency in Children
Genetic Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-03-27

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 168

Registration Number: NCT01563926

Locations: 🇮🇱
Novo Nordisk Investigational Site, Tel - Aviv, Israel

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Bleeding During/Following Surgery

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 208

Registration Number: NCT01563458

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Phase 2

Completed

Conditions: Trauma
Acquired Bleeding Disorder

Interventions: Drug: placebo
Drug: activated recombinant human factor VII

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 283

Registration Number: NCT01563523

Locations: 🇬🇧
Novo Nordisk Investigational Site, Birmingham, United Kingdom

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Healthy
Haemophilia B With Inhibitors

Interventions: Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-27

Last Posted Date: 2017-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 39

Registration Number: NCT01563471

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy